Home
About
Overview
Sharing Data
ORCID
Help
History (178)
A toll-like receptor-4-interacting surfactant protein-A-derived peptide suppresses tumor necrosis factor-a release from mouse JAWS II dendritic cells.
Treatment and outcomes of epithelioid sarcoma of the spine.
Calcimycin
The future of healthy aging: translation of geroscience discoveries to public health practice.
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
See All 178 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. Curr Hematol Malig Rep. 2021 02; 16(1):32-39.
View in:
PubMed
subject areas
Animals
Antigens, CD19
Biological Products
B-Lymphocytes
Humans
Immunotherapy, Adoptive
Leukemia, B-Cell
Lymphoma, B-Cell
Receptors, Antigen, T-Cell
authors with profiles
Taha Al-Juhaishi